ORIC PHARMACEUTICALS, INC. Financing Cash Flow
ORIC PHARMACEUTICALS, INC. (ORIC) reported Financing Cash Flow of $61.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $828.00K, a 99.38% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $61.14M, a 555718.18% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.50M, a 160.87% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $109.45M, a 86765.87% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $245.26M, a 93.81% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $126.55M, a 47.74% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $85.66M, a 239.58% increase from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $25.23M, a 48.66% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $828.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $61.97M 10-Q · filed 2026-08-03 | $63.47M derived: sum of 3 quarters · filed 2026-08-03 | $172.92M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $61.14M 10-Q · filed 2026-05-04 | $62.64M derived: sum of 2 quarters · filed 2026-05-04 | $172.09M derived: sum of 3 quarters · filed 2026-05-04 | $306.39M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $110.95M derived: sum of 2 quarters · filed 2026-02-23 | $245.25M derived: sum of 3 quarters · filed 2026-08-03 | $245.26M 10-K · filed 2026-02-23 |
| 2025-09-30 | $109.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $243.75M derived: sum of 2 quarters · filed 2026-08-03 | $243.76M 10-Q · filed 2025-11-13 | $244.34M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $134.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $134.31M 10-Q · filed 2026-08-03 | $134.89M derived: sum of 3 quarters · filed 2026-08-03 | $135.01M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $11.00K 10-Q · filed 2026-05-04 | $586.00K derived: sum of 2 quarters · filed 2026-05-04 | $712.00K derived: sum of 3 quarters · filed 2026-05-04 | $1.53M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $575.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $701.00K derived: sum of 2 quarters · filed 2026-02-23 | $1.52M derived: sum of 3 quarters · filed 2026-02-23 | $126.55M 10-K · filed 2026-02-23 |
| 2024-09-30 | $126.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $942.00K derived: sum of 2 quarters · filed 2025-11-13 | $125.97M 10-Q · filed 2025-11-13 | $126.42M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $816.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $125.85M 10-Q · filed 2025-08-12 | $126.30M derived: sum of 3 quarters · filed 2025-08-12 | $126.33M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $125.03M 10-Q · filed 2025-05-05 | $125.48M derived: sum of 2 quarters · filed 2025-05-05 | $125.51M derived: sum of 3 quarters · filed 2025-05-05 | $210.69M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $453.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $484.00K derived: sum of 2 quarters · filed 2025-02-18 | $85.66M derived: sum of 3 quarters · filed 2025-02-18 | $85.66M 10-K · filed 2025-02-18 |
| 2023-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $85.20M derived: sum of 2 quarters · filed 2024-11-12 | $85.20M 10-Q · filed 2024-11-12 | $110.00M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $85.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $85.17M 10-Q · filed 2024-08-12 | $109.97M derived: sum of 3 quarters · filed 2024-08-12 | $109.97M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-06 | $24.79M derived: sum of 2 quarters · filed 2024-05-06 | $24.79M derived: sum of 3 quarters · filed 2024-05-06 | $25.21M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $24.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $24.79M derived: sum of 2 quarters · filed 2024-03-11 | $25.21M derived: sum of 3 quarters · filed 2024-03-11 | $25.23M 10-K · filed 2024-03-11 |
| 2022-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $416.00K derived: sum of 2 quarters · filed 2023-11-06 | $432.00K 10-Q · filed 2023-11-06 | $1.25M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $415.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $431.00K 10-Q · filed 2023-08-10 | $1.24M derived: sum of 3 quarters · filed 2023-08-10 | $49.83M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $16.00K 10-Q · filed 2023-05-08 | $829.00K derived: sum of 2 quarters · filed 2023-05-08 | $49.41M derived: sum of 3 quarters · filed 2023-05-08 | $49.13M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $813.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $49.40M derived: sum of 2 quarters · filed 2023-03-16 | $49.12M derived: sum of 3 quarters · filed 2023-03-16 | $49.13M 10-K · filed 2023-03-16 |
| 2021-09-30 | $48.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $48.30M derived: sum of 2 quarters · filed 2022-11-07 | $48.32M 10-Q · filed 2022-11-07 | $173.82M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$281.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$265.00K 10-Q · filed 2022-08-11 | $125.23M derived: sum of 3 quarters · filed 2022-08-11 | $124.89M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $16.00K 10-Q · filed 2022-05-09 | $125.51M derived: sum of 2 quarters · filed 2022-05-09 | $125.17M derived: sum of 3 quarters · filed 2022-05-09 | $252.16M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $125.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $125.16M derived: sum of 2 quarters · filed 2022-03-21 | $252.14M derived: sum of 3 quarters · filed 2022-03-21 | $250.51M 10-K · filed 2022-03-21 |
| 2020-09-30 | -$341.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $126.64M derived: sum of 2 quarters · filed 2021-11-08 | $125.02M 10-Q · filed 2021-11-08 | $124.96M derived: sum of 4 quarters · filed 2022-03-21 |
| 2020-06-30 | $126.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $125.36M 10-Q · filed 2021-08-10 | $125.30M derived: sum of 3 quarters · filed 2022-03-21 | $131.00M derived: sum of 4 quarters · filed 2022-03-21 |
| 2020-03-31 | -$1.63M 10-Q · filed 2021-05-06 | -$1.69M derived: sum of 2 quarters · filed 2022-03-21 | $4.01M derived: sum of 3 quarters · filed 2022-03-21 | $53.93M derived: sum of 4 quarters · filed 2022-03-21 |
| 2019-12-31 | -$61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $5.64M derived: sum of 2 quarters · filed 2022-03-21 | $55.56M derived: sum of 3 quarters · filed 2022-03-21 | $70.82M 10-K · filed 2022-03-21 |
| 2019-09-30 | $5.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $55.62M derived: sum of 2 quarters · filed 2020-11-05 | $70.89M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $49.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $65.19M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $15.26M 10-Q · filed 2020-05-20 | |||
| 2018-12-31 | $38.01M 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |